What distinguishes non-small cell from small cell lung cancer?

NSCLC groups lung carcinomas other than small cell type, with different cells of origin, generally slower growth, and a management framework that increasingly relies on molecular profiling, whereas small cell carcinoma is a distinct, rapidly proliferating neuroendocrine tumor.

Why does molecular testing matter in NSCLC?

Identifying driver alterations such as EGFR mutations or ALK rearrangements and biomarkers such as PD-L1 expression defines molecular subsets of the disease, which is why classification has expanded beyond histology alone.

Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the umbrella term for the lung carcinomas that are not small cell type, accounting for the large majority of lung cancer cases. It groups adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, which share a generally slower growth than small cell disease and an increasingly molecularly defined approach to classification.

Témakeresés ezzel: PaperMindHamarosanFind papers & topics

Tools & resources

Diák letöltése

Learn & explore

VideóHamarosan

Definition

Non-small cell lung cancer is a heterogeneous group of epithelial lung malignancies excluding small cell carcinoma, comprising principally adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and increasingly subclassified by molecular drivers.

Scope

This topic covers the histologic subtypes that make up NSCLC, the driver mutations and immunologic features that subdivide it, how it is staged, and the broad principles by which it is studied and managed. It is a reference entry on disease biology and classification, not individualized clinical guidance.

Key concepts

Adenocarcinoma subtype
Squamous cell carcinoma subtype
Large cell carcinoma subtype
Driver oncogenes (e.g., EGFR, ALK, KRAS, ROS1)
PD-L1 expression and immunotherapy
TNM stage and resectability
Tumor mutational burden
Targeted therapy vs immunotherapy vs chemotherapy categories

Mechanisms

NSCLC develops from bronchial or alveolar epithelium through stepwise accumulation of genetic alterations, frequently linked to tobacco carcinogen exposure, though adenocarcinoma also occurs in never-smokers. A defining advance has been the identification of actionable driver alterations, such as EGFR mutations and ALK rearrangements, that activate growth-signaling pathways and define molecular subsets; alongside these, expression of immune checkpoints such as PD-L1 underlies the response of some tumors to immune checkpoint inhibition. Histologic subtype, molecular profile, and TNM stage together frame how the disease behaves and is categorized.

Clinical relevance

Understanding the histologic and molecular subdivisions of NSCLC is central to interpreting modern thoracic oncology evidence and to appreciating why classification has shifted from histology alone toward integrated molecular profiling. This entry describes disease biology and how it is studied; it is not a basis for individual diagnosis or treatment, including any drug or dosing decisions.

Epidemiology

NSCLC constitutes the majority of all lung cancer diagnoses worldwide; smoking is the dominant risk factor, but adenocarcinoma in particular is also seen in people who have never smoked, and the global burden tracks the overall epidemiology of lung cancer as the leading cause of cancer death.

History

The category arose from the clinical recognition that lung carcinomas other than small cell type behave and respond similarly enough to be grouped for management purposes. Over the past two decades the field has moved from this histology-based grouping toward molecular classification, as the discovery of targetable driver alterations and immune checkpoint biology reshaped how NSCLC is defined and studied.

Debates

Histologic versus molecular classification of NSCLC: The traditional histologic grouping is increasingly overlaid by molecular subtyping based on driver alterations and biomarker expression, raising the question of how far classification should be reorganized around molecular rather than morphologic categories.

Seminal works

herbst-2018
thai-2021
goldstraw-2016

Frequently asked questions

What distinguishes non-small cell from small cell lung cancer?: NSCLC groups lung carcinomas other than small cell type, with different cells of origin, generally slower growth, and a management framework that increasingly relies on molecular profiling, whereas small cell carcinoma is a distinct, rapidly proliferating neuroendocrine tumor.
Why does molecular testing matter in NSCLC?: Identifying driver alterations such as EGFR mutations or ALK rearrangements and biomarkers such as PD-L1 expression defines molecular subsets of the disease, which is why classification has expanded beyond histology alone.